It is a lie to claim that the company deferred the ABSSSI trial "to maximize shareholder value." They did not. They were very clear that they were devoting company resources to quicker, cheaper clinical trials, and that spending tens of millions on a lengthy (several years) clinical trial was not prudent.

Any further lies will be deleted.